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Discovery cohort: For the initial mass-spectrometry analysis, we selected a total of 45 patients 3 enrolled in the clinical study #1 and #2. This consisted of 40 patients with laboratory confirmed 4 CNS infections: TBM (n=20), BM (n=10), encephalitis (n=10), and five patients with non-CNS 5 infection ( Fig. 1) . Of the 10 patients with BM, seven were infected with S. suis and three with S. 6 pneumoniae. Of the patients with encephalitis, herpes simplex virus was the cause in 5, DENV 7 in 3, JEV in 1 and mumps virus in 1. The cohort's clinical characteristics and outcomes are 8 presented in Table S2 . 9 Validation cohort: To validate the results of the discovery phase, we selected 364 consecutive 1 0
adult patients enrolled in the study #3 (Figure 1) . The baseline characteristics, clinical outcomes, 1 1
and results of etiological investigations of the cohort are presented in Table S2 and respectively. Of the 44 laboratory-confirmed bacterial meningitis patients, S. suis, was the 1 9
commonest cause (n=20), followed by S. pneumoniae (n=6) and Escherichia coli (n=5). Of the 2 0 29 patients with laboratory confirmed viral encephalitis, HSV was the commonest cause (n=11), 2 1 followed by VZV (n=7), and DENV (n=5) (Figure. 1 ).
2
Biomarker discovery 1 Tandem mass-spectrometry analysis of 45 CSF samples of the discovery cohort identified a total 2 of 1,012 proteins. Of these, 891 were included in the analysis based on the number of peptides 3 and sequence coverage. Subsequent analysis identified a total of 729 quantifiable protein 4 signatures that were clinical-entity specific, especially for patients with BM (Figure 2A ). Of 5 these, 60 and 19 were significantly expressed in the CSF of patients with BM and TBM, 6 respectively (Table S3 ). No diagnostic biomarker candidate was found in patients with viral 7 encephalitis.
8
Of the protein candidates identified in the BM group, lipocalin 2 (LCN2), also known as 9 neutrophil gelatinase-associated lipocalin, had a sensitivity of 1 (95%CI: 0.73-1) and a In order to verify the mass-spectrometry findings, we performed quantitative ELISA analysis of ( Figure S1 ). Of the patients with BM, CSF LCN2 levels were higher in those with a confirmed 9 diagnosis than in those without a bacteria identified ( Figure S1 ), while the duration of illness at 1 0 enrolment was similar between the two groups (data not shown). ng/ml) and a diagnostic odd ratio (DOR) of 44.8 or above ( Figure 3B ). for BM ( Figure 4C ). More specifically, in terms of discriminating between BM and all other 5 CNS infections, the predictive values for BM based on AUROC curves and DOR increased from to the CSF parameters based model ( Figure 4C ). Similar results were obtained when assessing 8 the utility of LCN2 in discriminating between BM and other specific clinical entities (TBM or 9 encephalitis) ( Figure 4D and Figure S2 ). LCN2 did not, however, help distinguish confirmed 1 0 from suspected BM (Table S4 ).
1 1 CSF and plasma LCN2 (Spearman R: 0.37, P=0.08), suggesting that LCN2 is intrathecally 1 8
Association between CSF and plasma concentrations of LCN2
produced in response to the bacterial invasion of the CNS. and anti-NMDAR encephalitis). Additionally, we also compared the diagnostic performance of 2 0
LCN2 against that of CSF markers commonly used as part of routine care worldwide. As such, and for the first time provide strong evidence that LCN2 is a highly sensitive biomarker for 1 discriminating BM from a broad-spectrum of CNS infections.
2
The differences in CSF LCN2 levels between laboratory confirmed and clinically suspected BM 3 groups pointed to the association between the host responses and an on-going infection (i.e. the 4 presence of a bacterial pathogen in clinical samples at the time of collection). This is in 5 agreement with previous studies showing that the decrease of plasma LCN2 level was correlated 6 with the success of antibiotic treatment in patients with bacteremia (15). Collectively, CSF 7 LCN2 might also be a useful marker for treatment response assessment. Therefore, further 8 research should aim at defining the optimal cut-off of LCN2 concentrations that can be used to 9 inform the administration or withdrawal of antibiotics in patients with BM.
1 0
Our study has some of limitations. A part from LCN2, we did not explore the utility potential of 1 1 the other biomarker candidates identified in the discovery cohort (e.g. CSF cathelicidin for BM 1 2 (22)) detected by original mass-spectrometry analysis). Likewise, we did not assess the CNS infections such as procalcitonin and heparin-binding protein for BM (7, 9, (23) (24) (25) , and CSF 1 5 lipoarabinomannan for TBM (26). Additionally, we only focused our analysis on adults, leaving 1 6
the utility potential of LCN2 in pediatric CNS infections unknown.
7
In spite of these limitations, the strengths of our study include that it represents the largest and 1 8 most comprehensive mass-spectrometry-based biomarker discovery investigation focusing on 1 9
patients with various clinical entities of CNS infections to date (7). The study was also conducted 2 0
in Vietnam and therefore includes all the major infectious causes of CNS infections seen 2 1 globally. Additionally, because our study was conducted at a single major tertiary referral 1 4
hospital, all routine diagnostic approaches and patient assessments were consistent over the 1 course of the study, thereby minimizing potential bias.
2
To summarize, our study showed for the first time that LCN2 is a highly sensitive biomarker for 3 accurate prediction of BM in adults, especially when used alongside other standard CSF 4 parameters. Prospective studies are needed to assess the utility potential of LCN2 in the 5 diagnosis and management of CNS infections, including children, and whether it can be used in 6 settings with limited laboratory capacity to improve outcomes from these devastating conditions. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis. computational platform for comprehensive analysis of (prote)omics data. Nat Methods. from label-free quantitative mass-spectrometry analysis of 45 patients of the discovery phase. 
